Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-22-019610
Filing Date
2022-03-17
Accepted
2022-03-17 16:38:01
Documents
2
Period of Report
2022-03-07

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1642
2 POA DOCUMENT poa.txt EX-24 3697
  Complete submission text file 0001209191-22-019610.txt   6832
Mailing Address 22 FIRSTFIELD ROAD SUITE 250 GAITHERSBURG MD 20878
Business Address 22 FIRSTFIELD ROAD SUITE 250 GAITHERSBURG MD 20878 301-517-5556
MAXCYTE, INC. (Issuer) CIK: 0001287098 (see all company filings)

EIN.: 522210438 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 8731 Services-Commercial Physical & Biological Research

Mailing Address C/O MAXCYTE, INC. 22 FIRSTFIELD ROAD, SUITE 110 GAITHERSBURG MD 20878
Business Address
Sumen Cenk (Reporting) CIK: 0001917133 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40674 | Film No.: 22749093